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In addition to oxytocin (OT), vasopressin (AVP) and their respective neurophysins (NPs), another 
[%]cysteine incorporating component is present in the guinea pig neurohypophysis. Gel filtration and Con 
A affinity chromatography revealed that this component was larger than NP and was glycosylated. NP- 
immunoreactivity was assessed using antisera which distinguish the OT- and AVP-related NPs. Whilst the 
anti-NP antiserum detected only one component (guinea pig NP), the anti-NP antiserum detected both NP 
and the glycosylated 35S-labelled component. These results suggest hat a significant amount of NP in 
guinea pig neural lobes bears a glycopeptide extension and represents a partially processed form of the 
AVP precursor in this species. 
AVP Precursor Neurophysin Glycopeptide Biosynthesis Intermediate 
1. INTRODUCTION 
The neurohypophysial peptide hormones, oxy- 
tocin (OT) and vasopressin (AVP) are biosyn- 
thesised as part of larger precursors [l-3] together 
with their carrier proteins, the neurophysins (NPs). 
After biosynthesis in the magnocellular perikarya 
of the hypothalamic supra-optic and paraven- 
tricular nuclei, the precursors are packaged into 
neurosecretory granules and transported to the 
nerve terminals in the posterior pituitary glands. 
During transport, the precursors are processed by 
proteolytic cleavage and amidation [4,5] producing 
the mature neurosecretory products, stored in the 
neural lobe. 
Hypothalamic injection of [35S]cysteine has been 
used to establish several steps in the biosynthesis of 
these peptides in the dog and rat [6,7]. Radiolabel 
is incorporated into the cysteine-rich neurosecre- 
tory products which can be analysed after isolation 
from different parts of the hypothalamoneuro- 
hypophysial system [8]. Using these techniques in 
the guinea pig, we have recently demonstrated, in 
addition to the expected neurosecretory products, 
significant amounts of an additional biosynthetic 
component in the neural lobe [9], which we pro- 
posed was a partially processed form of the AVP- 
precursor. In this paper, we have now further 
characterised this component, and suggest hat it 
contains the NP sequence with an additional 
glycopeptide attached at its carboxyl terminus 
[lO,ll]. 
2. MATERIALS AND METHODS 
Under halothane/NzO anaesthesia, guinea pigs 
(Hartley, 500-700 g) were given bilateral injections 
of [35S]cysteine (1000 Ci/mmol, Amersham Inter- 
national) into the paraventricular nuclei (40 pCi, 
2 x 2 /rl) as in [9]. After 24 h the neural lobes were 
removed, homogenised in 100 mM HCI (200 
&lobe) and centrifuged (8OOOxg, 2 min). Gel 
filtration was performed on a column (0.9 x 90 cm) 
of Sephadex G-75 (Pharmacia GB) equilibrated 
324 
Published by Elsevier Science Publishers B. V. 
00145793/83/$ 3.00 0 1983 Federation of European Biochemical Societies 
Volume 163, number 2 FEBS LETTERS November 1983 
and eluted with 100 mM HCl containing 0.2% 
bovine serum albumin (BSA, fraction V, Sigma 
London), by upward flow at 6 ml/h. The 35S 
radioactivity of the fractions was estimated by li- 
quid scintillation counting. Reverse-phase high 
pressure liquid chromatography (HPLC) was per- 
formed on a Spectraphysics 87~ system using a 
column (70 x 4.6 mm) of Nucleosil 5 ,uCS, eluted 
with a gradient of acetonitrile (CH3CN) in 0.1% 
trifluoroacetic acid (TFA) as in [9]. Buffer A, 
0.1% TFA; Buffer B, 60% CH3CN in buffer A. 
Affinity chromatography on concanavalin A 
columns (2 ml, Con A-Sepharose 4B, Pharmacia) 
was carried out using a column buffer of the 
following composition (mM): CaCl2, 1; MnClz, 1; 
MgC12, 1; Tris, 50; NaCl, 1000; Triton X-100, 
0.1% (pH 7.4). Con A-bound material was eluted 
by the addition of 0.5 M a-D-methyl mannoside 
(Sigma, UK) to the column buffer. 
NP-like immunoreactivity was tested using an- 
tisera against porcine NPs (unpublished) which are 
able to distinguish OT-related NP (NPor), from 
AVP-related NP (NPAvP) and which cross-react 
with the equivalent NPs in the guinea pig. The 
assay procedure was as in [12]. Anti-NPAvp serum 
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Fig. 1. Gel filtration of f35S]cysteine-labelled neural lobe 
extract. An acid extract of one neural lobe, removed 24 
h after hypothalamic injection of [3SS]cysteine was 
chromatographed on a Sephadex G-75 column (90 x 0.9 
cm). The column was eluted by upward flow at a rate of 
6 ml/h. Fractions (1 ml) were collected and aliquots (250 
pi) were measured for [3’S]cysteine radioactivity. The 
r~aining portions of the fractions corresponding to the 
major radiolabelled components (peaks A-C) were 
pooled and lyophilized. The column was calibrated using 
thyroglobulin (V,), soya bean trypsin inhibitor (21 kDa), 
cytochrome c (12.8 kDa) and [3sS]cysteine (K) as Mr 
Fraction Number 
Fig.2. HPLC identification of radiolabelled components 
separated by gel filtration. Pooled, radiolabelled peaks 
A-C from fig. 1 were redissolved in water and subjected 
to HPLC. Fractions (1 ml) were collected and counted 
for 35S radioactivity. Upper panel, HPLC of peak A, 
fig.1; middle panel, HPLC of peak B, fig-l; lower panel 
HPLC of peak C, fig.1. Arrows show the retention times 
of OT, AVP, NPAVP, NPor and NP-GP. Dotted lines 
markers. show elution gradient, 
was used at a dilution of 1: 10000, anti-NPor at 
1: 60 000. Porcine NPor and NPAVP were used as 
tracers after iodination [ 131 and immunoreactivity 
in the samples was expressed in terms of their cor- 
responding porcine NP standards. 
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3. RESULTS 
Sephadex G-75 chromatography was performed 
on acid extracts of neural lobes from animals in- 
jected 24 h previously with [3’S]cysteine (fig.1). 
Three major radioactive peaks emerged (A-C) 
with approximate M; values of 18, 10 and < 2 kDa. 
Fractions corresponding to these peaks were pool- 
ed, lyophilized, redissolved in water and subjected 
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Fig.3. Con A-Sepharose affinity chromatography of 
NPs and NP-GP. %-labelled material from HPLC 
(fig.2) was subjected to Con A-Sepharose affinity 
chromatography. Fractions (1 ml) were collected and 
counted for 35S-radioactivity. Upper panel, Con A 
chromatography of 36S-NPs, NP was not retained on the 
column. Lower panel, Con A chromatography of “S- 
NP-GP. Most of the “S counts in this fraction were 
retained on the column, and were eluted by CY-D- 
Fig.4. Neurophysin-related immunoreactivity in guinea 
pig neural lobes. An acid extract of a guinea pig neural 
lobe (i/3) was subjected to HPLC. Fractions (0.5 ml) 
were collected and aliquots (IO pl) from the fractions 
were assayed for NPor (open circles) and NPAVP (closed 
circles). Immunoreactivity is expressed relative to the 
appropriate porcine NP standard. Arrows show the 
retention times of guinea pig NPAVP, NPor and NP-GP. 
mannoside (arrow). Dotted line shows elution gradient. 
to reverse phase HPLC to identify the radiolabell- 
ed components (fig.2). The 18 kDa material eluted 
late in the gradient (fig.ZA) in the position of the 
proposed neurophysin-glycopeptide intermediate 
NP-GP [9]. The 10 kDa material was further 
resolved (fig.ZB) into NPAVP and NPor whilst the 
low-M, [35S]cysteine-incorporating material con- 
tained AVP and OT (fig.2C). HPLC-purified NPs 
(fig.2B) and the NP-GP intermediate (fig.2A) were 
further chromatographed on Con A-Sepharose, 
and the results are shown in fig.3. As expected, 
35S-labelled NPs were not retained on the column, 
whereas the material from peak A did bind to Con 
A and was eluted with a-methyl mannoside. A 
neural lobe extract was then subjected to HPLC 
and fractions tested for NP-immunoreactivity 
(fig.4). The anti-NPoT antisera detected only one 
component (NPor) whereas anti-NPAvp im- 
munoreactivity was found in the positions of both 
NPAVP and the NP-GP component. 
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4. DISCUSSION 
The primary structures of the bovine and rat 
AVP precursors, and the bovine OT precursor 
have recently been deduced from cDNA sequen- 
cing [14-161. Both precursors contain the 
nonapeptide hormone sequence connected to the 
corresponding NP by a Gly-Lys-Arg sequence. 
The NP sequence in the AVP precursor is extended 
at its C-terminus by a 39 residue glycopeptide, 
whereas the NP sequence in the OT precursor ter- 
minates with a single additional histidine residue, 
and is therefore not glycosylated [3,17]. We have 
recently identified a component in the neural lobe 
of the guinea pig which appeared to be a biosyn- 
thetic intermediate in the AVP system [9]. This 
component could be separated from the classical 
neurohypophysial products (OT, AVP, NPs) by 
HPLC, in a peak which incorporated both 
[35S]cysteine and [3H]fucose, and which contained 
immunoreactive NP, but not OT or AVP. Isotope 
incorporation ratios suggested that this material 
was a partially processed form of the AVP precur- 
sor comprising NP with its C-terminal glycopep- 
tide still attached. 
In the present experiments, gel filtration and 
HPLC of 35S-labelled pituitary extracts established 
that this material had a higher M, than NP, consis- 
tent with it being a processing intermediate. Affini- 
ty chromatography on Con A-Sepharose confirm- 
ed that the 3’S-incorporating material was 
glycosylated, suggesting that it related to the AVP 
precursor, rather than the OT precursor. This 
assignment is further supported by measurements 
of the NP immunoreactivity of the component. 
Previous work showing the proposed intermediate 
to be NP-immunoreactive [9] used an antiserum 
which was specific for guinea pig NP but could not 
distinguish between NPAVP and NPor. By using 
heterologous antisera which can differentiate be- 
tween the guinea pig NPs we have now confirmed 
that the intermediate relates to the NPAVP system. 
In view of the known structure of the AVP precur- 
sor in other species [14], the simplest explanation 
for our results is that significant amounts of a par- 
tially processed AVP precursor are present in the 
guinea pig neural lobe as an intact NP-GP 
sequence. 
Rat neural lobes apparently contain little if any 
similar intermediate [18], but higher M, [35S]- 
cysteine-incorporating material has been observed 
in gel filtration studies of rat neural lobe extracts 
at early times after labelling [ 191, and glycosylated 
NP material has been reported in bovine pituitary 
extracts [20]. Perhaps the unusually high AVP : OT 
ratio in the guinea pig pituitary [21] favours the 
detection of AVP-related biosynthetic intermedi- 
ates in this species. If the guinea pig AVP precur- 
sor has the same structure and cleavage sites as the 
bovine and rat precursors, then the link between 
AVP and NP contains a dibasic residue, a common 
site for precursor processing [4]. NP is linked to 
the glycopeptide via a single basic residue [14], a 
site which is not usually involved in processing 
[22,23]. In this context, it is interesting that pro- 
cessing would appear to begin with the removal of 
AVP, followed by cleavage of the C-terminal 
glycopeptide at a later stage [9]. 
Although the structure of this NP-GP compo- 
nent suggests it is a biosynthetic intermediate bet- 
ween the AVP precursor and the final neurohypo- 
physial secretory products, it remains to be deter- 
mined whether the pituitary content of NP-GP is 
further processed, or whether this molecule re- 
presents a mature neurosecretory product in the 
guinea pig neural lobe. 
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